Core Insights - Wellgistics Health, Inc. (NASDAQ: WGRX) is set to appear live on YouTube on July 22, 2025, at 1:00 PM EST to discuss its recent performance and future strategy [1][2] Group 1: Company Overview - CEO Brian Norton will lead an unfiltered discussion on WGRX's recent momentum, stock performance, and market outlook [2] - The company is recognized for its role in pharmaceutical distribution and healthcare technology [1] Group 2: Event Details - The live session will be hosted on the Floorstocks channel, which focuses on amplifying rising public companies [2][4] - Retail investors will have the opportunity for direct engagement during the session [2] Group 3: Strategic Insights - The discussion will cover WGRX's disruptive strategy in healthcare distribution and direct-to-patient services [5] - WGRX is integrating XRP blockchain payments into healthcare transactions to enhance efficiency and global accessibility [5] - The session will analyze the recent surge in stock activity and market dynamics [5]

Core Insights - Cardinal Health plans to release its fourth-quarter and year-end financial results for fiscal year 2025 on August 12, prior to the opening of trading on the New York Stock Exchange [1] - A webcast discussion of these results will begin at 8:30 a.m. Eastern on the same day [1] Access Information - The webcast and corresponding slide presentation can be accessed via Cardinal Health's Investor Relations page without the need for an access code [2] - Presentation slides and a replay of the webcast will be available on the Investor Relations page for 12 months [2] Company Overview - Cardinal Health is a distributor of pharmaceuticals and specialty products, a global manufacturer and distributor of medical and laboratory products, and a supplier of home-health and direct-to-patient products and services [3] - The company operates nuclear pharmacies and manufacturing facilities and provides performance and data solutions [3] - Cardinal Health emphasizes a customer-centric focus that drives continuous improvement and leads to innovative solutions that enhance people's lives [3]

Core Insights - Cardinal Health has launched the Cardinal Health™ One Voice Initiative aimed at providing financial assistance to state pharmacy associations to support independent pharmacists' advocacy efforts [1][2][3] - The initiative is part of Cardinal Health's ongoing commitment to advocate for independent pharmacies and enhance their influence in healthcare policy discussions [2][3] - Financial contributions will be made to state pharmacy associations, with support for additional states contingent on advocacy opportunities for the independent pharmacy community [3][4] Company Overview - Cardinal Health operates as a distributor of pharmaceuticals and specialty products, a global manufacturer and distributor of medical and laboratory products, and a provider of home-health and direct-to-patient products and services [5] - The company emphasizes a customer-centric focus that drives continuous improvement and innovation in solutions that enhance people's lives [5]

Summary of Cardinal Health's 2025 Investor Day Company Overview - **Company**: Cardinal Health (CAH) - **Event**: 2025 Investor Day held on June 12, 2025 Key Industry Insights - **Healthcare Industry Role**: Cardinal Health positions itself as a crucial link in the healthcare supply chain, connecting manufacturers to patients through a complex distribution network [7][31] - **Market Trends**: The aging population and ongoing healthcare innovations are driving demand in the healthcare sector, providing a "rising tide" of volume for the industry [32] Core Business Strategies - **Core Distribution Focus**: The company emphasizes strengthening its core distribution business, which is foundational for future growth and profitability [19][20] - **Specialty Solutions Growth**: Specialty solutions remain the highest growth priority, with a focus on organic and inorganic investments in this segment [21][50] - **Investment in Automation**: Cardinal Health is investing in automation to enhance distribution efficiency and capacity, which is critical for meeting customer needs [13][40] Financial Performance and Guidance - **Earnings Growth**: The company raised its fiscal 2025 EPS guidance and confirmed a long-term EPS growth target of 12-14% for fiscal years 2026-2028 [27][55] - **Capital Deployment**: Over the past two years, Cardinal Health has returned nearly $3 billion to shareholders while also increasing capital expenditures by over 50% compared to four to five years ago [25][24] Specialty Solutions and Partnerships - **Specialty Alliance Formation**: The formation of the Specialty Alliance aims to enhance capabilities in gastroenterology, urology, and oncology, leveraging existing infrastructure and expertise [41][90] - **Managed Service Organizations (MSOs)**: The company is expanding its MSO platforms to support independent physicians, providing back-office support and enhancing care delivery [92] Innovations and Technology - **New Distribution Centers**: Cardinal Health is launching a new flagship distribution center with advanced automation technology to improve service levels and efficiency [40][69] - **Technology Investments**: Significant investments in technology infrastructure, including a new ordering platform (Vantas HQ), are aimed at improving customer experience and operational efficiency [70] Market Position and Competitive Advantage - **Diverse Customer Base**: The company serves a wide range of customers, including independent pharmacies, health systems, and specialty practices, allowing it to adapt to various market needs [64][65] - **Strategic Sourcing**: Strong relationships with brand manufacturers and partnerships with CVS enhance product availability and cost efficiency, contributing to profitable growth [66] Future Outlook - **Growth Opportunities**: Cardinal Health anticipates significant growth in its specialty segment, with expectations of doubling the number of supported products in the next three years [98][106] - **Resilience in Cash Flow**: The company has demonstrated strong cash flow resilience, with a consistent upward trend over long periods, indicating robust operational performance [36][37] Conclusion - **Commitment to Innovation**: Cardinal Health is focused on continuous improvement and innovation to meet evolving customer and patient needs, positioning itself for sustained growth in the healthcare industry [34][55]

Core Insights - Cardinal Health is hosting an Investor Day to discuss growth strategies and long-term financial outlook [2][3] - The company emphasizes its strong foundation and significant future growth opportunities [3] Strategic Updates - Cardinal Health is focusing on expanding its Pharmaceutical and Specialty Solutions, particularly in Specialty and higher-margin businesses [4] - The Specialty Alliance platform will include the recently acquired GI Alliance and the new Urology Alliance [5] - The MSO platforms now support approximately 2,200 providers across 28 states [6] Biopharma Solutions - Continued investments in Biopharma Solutions are announced, with expansions into oncology and other therapeutic areas [7] - The Sonexus™ Access and Patient Support platform is expected to more than double its supported therapies by fiscal year 2028 [7] Pharmaceutical Distribution - The Consumer Health Logistics Center in Ohio is set to be fully operational by July 2025, aimed at increasing capacity and efficiency [8] - Plans for a new forward distribution center with advanced automation technology are underway [9] Financial Guidance - FY25 non-GAAP diluted EPS guidance is raised to $8.15 to $8.20, with preliminary FY26 guidance set at $9.10 to $9.30 [10][18] - Long-term targets for non-GAAP diluted EPS growth are set at 12% to 14% for FY26 to FY28 [20] Capital Deployment - The company plans to invest at least $600 million annually in capital expenditures and anticipates at least $750 million in share repurchases each year for the next three years [21]

Greensboro, NC, June 04, 2025 (GLOBE NEWSWIRE) -- Global Technologies, LTD (OTCPK: GTLL), a public, multi-operational company focused on innovation in health and wellness, recently announced corporate developments and commercial milestones signaling a bold pivot in strategy and leadership. Over the past 90 days, GTLL has responded proactively to external FDA regulatory shifts that disrupted several industry sectors, including GLP-1 compounding and semaglutide supply. These changes catalyzed GTLL's sharpened ...

ITASCA, IL, May 15, 2025 (GLOBE NEWSWIRE) -- Lakeside Holding Limited (“Lakeside” or the “Company”) (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market operating through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd., today announced financial results for its fiscal 2025 third quarter and nine months ended March 31, 2025. Management Commentary "The third quarter and first nine months of fiscal ...

Core Insights - McKesson Corporation reported fourth-quarter fiscal 2025 adjusted EPS of $10.12, exceeding the Zacks Consensus Estimate of $9.81 by 3.2%, and showing a year-over-year increase of 63.8% [1] - The company's revenue for the quarter was $90.82 billion, which missed the Zacks Consensus Estimate by 3.1%, but represented an 18.9% increase year-over-year, driven by strong performance in the Pharmaceutical segment, particularly in specialty products and oncology [2][5] Revenue and Segment Performance - U.S. Pharmaceutical segment revenues reached $83.2 billion, up 21% year-over-year, primarily due to increased prescription volumes and growth in the oncology platform [5] - The International segment reported revenues of $3.5 billion, down 2% year-over-year, attributed to the divestiture of the Canada-based Rexall and Well.ca retail businesses, although higher pharmaceutical distribution volumes partially offset this decline [8] - Medical-Surgical Solutions segment revenues totaled $2.9 billion, up 1% year-over-year, driven by higher volumes of specialty pharmaceuticals [9] - Prescription Technology Solutions segment revenues were $1.3 billion, reflecting a 14% year-over-year increase due to growth in technology services and third-party logistics [10] Profitability and Margins - Gross profit for the quarter was $3.39 billion, up 2.2% year-over-year, representing 3.7% of net revenues, a decrease of nearly 60 basis points year-over-year [12] - Adjusted operating income was $1.72 billion, an 18.5% increase from the prior year, with an operating margin of 1.9%, remaining flat year-over-year [12] Strategic Initiatives and Future Outlook - McKesson announced plans to separate its Medical-Surgical Solutions segment into an independent company to enhance strategic opportunities [10] - The company provided EPS guidance of $36.75-$37.55 for fiscal 2026 but did not offer total and segmental sales outlook due to the potential spin-off [14] - McKesson is investing in advanced technologies, including AI and data analytics, to improve operational efficiency and patient care outcomes [18] - The company emphasized its commitment to health equity and expanding access to pharmacies in underserved areas [18] Market Performance - McKesson's shares rose 2.3% in after-hours trading on May 8, reflecting positive bottom-line performance and plans for divestiture [4] - Year-to-date, McKesson's shares have gained 21.1%, contrasting with a 1.6% decline in the industry and a 4.9% decline in the S&P 500 Index [4]

Core Insights - McKesson reported revenue of $90.82 billion for the quarter ended March 2025, reflecting a 19% increase year-over-year, with EPS at $10.12 compared to $6.18 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $93.7 billion by 3.08%, while the EPS exceeded the consensus estimate of $9.81 by 3.16% [1] Revenue Breakdown - U.S. Pharmaceutical revenue was $83.17 billion, a 20.9% increase year-over-year, but below the average estimate of $85.79 billion [4] - Prescription Technology Solutions revenue reached $1.34 billion, up 13.5% year-over-year, slightly below the average estimate of $1.36 billion [4] - International revenue was $3.46 billion, showing a year-over-year decline of 2.5%, compared to the average estimate of $3.55 billion [4] - Medical-Surgical Solutions revenue was $2.85 billion, a 0.6% increase year-over-year, exceeding the average estimate of $2.79 billion [4] Adjusted Operating Profit - Adjusted Operating Profit for U.S. Pharmaceutical was $1.05 billion, matching the average estimate [4] - Adjusted Operating Profit for International was $102 million, surpassing the average estimate of $96.42 million [4] - Adjusted Operating Profit for Corporate was -$165 million, slightly worse than the average estimate of -$160.18 million [4] - Adjusted Operating Profit for Prescription Technology Solutions was $285 million, exceeding the average estimate of $267.80 million [4] - Adjusted Operating Profit for Medical-Surgical Solutions was $285 million, slightly above the average estimate of $283.33 million [4] Stock Performance - McKesson's shares returned +7.5% over the past month, underperforming compared to the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - The company reported a full year consolidated revenue growth of 16%, reaching a record level of $359 billion, with adjusted earnings per diluted share at $33.5, exceeding expectations and reflecting a year-over-year EPS growth of 20% [5][40][42] - Fourth quarter earnings per diluted share increased 64% to $10.12, driven by a lower effective tax rate and strong operational growth across the business [32][29] - Operating profit for the full year increased 15% to $5.6 billion, with significant contributions from the U.S. Pharmaceutical and Prescription Technology Solutions segments [41][42] Business Line Data and Key Metrics Changes - The U.S. Pharmaceutical segment saw revenues increase by 21% to $83.2 billion, driven by increased prescription volumes and growth in specialty product distribution [33][22] - The Prescription Technology Solutions segment reported a revenue increase of 13% to $1.3 billion, with operating profit rising 34% to $285 million, reflecting increased prescription transaction volumes [34][35] - The Medical Surgical Solutions segment experienced a 1% revenue increase to $2.9 billion, with operating profit up 15% to $285 million, benefiting from cost optimization initiatives [37][36] Market Data and Key Metrics Changes - The Canadian business, part of the international segment, reported revenues of $3.5 billion, a decrease of 2% due to the divestiture of certain businesses, but operating profit increased by 9% [38][24] - The company anticipates continued growth in the Canadian distribution business, partially offset by the impact of previous divestitures [58] Company Strategy and Development Direction - The company is focusing on strategic acquisitions in oncology and biopharma services, including the acquisition of a controlling interest in Prism Vision and Core Ventures, aimed at enhancing community-based care [6][12][49] - A strategic decision was made to separate the Medical Surgical segment into an independent company to enhance operational focus and capital deployment [19][27] - The company plans to continue investing in technology, automation, and AI to improve operational efficiencies and customer service [7][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to maintain momentum and deliver strong results in fiscal 2026, with anticipated revenue growth of 11% to 15% and operating profit growth of 8% to 12% [43][44] - The company remains committed to maximizing shareholder value through disciplined portfolio management and strategic capital deployment [27][62] Other Important Information - The company returned $3.5 billion to shareholders in fiscal 2025, including $3.1 billion through share repurchases [42] - Free cash flow for the fourth quarter was robust at $7.5 billion, driven by strong operating results [39] Q&A Session Summary Question: Impact of Medicare Part B on ASPs - Management indicated that there are currently no concrete announcements regarding Medicare Part B impacts, and any potential changes would likely face legal challenges [65][66] Question: Tariff Impacts on Business - Management is closely monitoring the tariff landscape and believes that current assessments have been incorporated into guidance, with no material impact anticipated on fiscal 2026 results [75][81] Question: Urgency in Capital Deployment for Biopharma Services - Management stated that the urgency for capital deployment remains consistent, driven by strategic alignment and financial discipline [85][88] Question: Long-term Pharma Growth Rate Guidance - Management noted that the increase in long-term guidance reflects a stable environment for prescription utilization and successful capital deployment in oncology and other specialties [92][96]